Fifth Third Bancorp Has $4.87 Million Stock Position in Insulet Corporation $PODD

Fifth Third Bancorp boosted its position in shares of Insulet Corporation (NASDAQ:PODD) by 170.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 23,228 shares of the medical instruments supplier’s stock after purchasing an additional 14,644 shares during the quarter. Fifth Third Bancorp’s holdings in Insulet were worth $4,874,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. NewEdge Advisors LLC boosted its position in Insulet by 44.8% during the 1st quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock worth $54,000 after acquiring an additional 64 shares during the last quarter. Cresset Asset Management LLC increased its holdings in shares of Insulet by 7.3% in the second quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier’s stock valued at $813,000 after purchasing an additional 177 shares during the last quarter. Cerity Partners LLC raised its position in shares of Insulet by 68.7% in the second quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier’s stock valued at $5,423,000 after purchasing an additional 7,030 shares during the period. Sei Investments Co. boosted its stake in Insulet by 27.4% in the 2nd quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock valued at $43,245,000 after purchasing an additional 29,584 shares during the period. Finally, Treasurer of the State of North Carolina grew its position in shares of Insulet by 2.5% during the 2nd quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier’s stock worth $10,290,000 after purchasing an additional 791 shares in the last quarter.

Insider Activity

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was bought at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the acquisition, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.36% of the company’s stock.

Insulet Trading Down 0.2%

Shares of Insulet stock opened at $164.06 on Friday. The company has a 50 day simple moving average of $153.00 and a two-hundred day simple moving average of $206.90. Insulet Corporation has a 1 year low of $138.79 and a 1 year high of $354.88. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. The firm has a market cap of $11.36 billion, a PE ratio of 38.15, a PEG ratio of 1.15 and a beta of 1.11.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. During the same quarter in the previous year, the company posted $1.02 EPS. Insulet’s quarterly revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Analysts expect that Insulet Corporation will post 6.45 earnings per share for the current fiscal year.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet provided an update on its ongoing EVOLUTION T1D clinical study, which is testing a next step in automated insulin delivery and could support the long-term growth story for its Omnipod platform. Article link
• Neutral Sentiment: Several firms issued deadline reminders and investor alerts related to the already-filed securities class action, keeping the lawsuit in focus but not adding new allegations. Article link
• Neutral Sentiment: Additional law-firm notices reiterated the August 31 lead-plaintiff deadline, underscoring ongoing legal risk but mainly serving as promotional updates rather than fresh company developments. Article link
• Negative Sentiment: Multiple securities-fraud class action notices highlighted alleged investor harm tied to Insulet’s manufacturing quality and prior device corrections, which is likely weighing on sentiment and shares. Article link

Analyst Ratings Changes

Several research firms recently issued reports on PODD. William Blair started coverage on shares of Insulet in a research report on Wednesday, May 20th. They set an “outperform” rating on the stock. Canaccord Genuity Group decreased their target price on Insulet from $435.00 to $249.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Deutsche Bank Aktiengesellschaft began coverage on Insulet in a report on Tuesday, June 23rd. They set a “buy” rating and a $190.00 price objective for the company. Piper Sandler lowered their price target on Insulet from $360.00 to $210.00 in a research report on Wednesday, May 6th. Finally, Rothschild & Co Redburn reiterated a “neutral” rating and set a $220.00 target price (down from $380.00) on shares of Insulet in a research note on Friday, April 24th. Twenty-two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Insulet has a consensus rating of “Moderate Buy” and a consensus target price of $235.25.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.